Abstract:

 Objective To evaluate the expression of SH3GL1 and p?ERK in hepatocellularcarci-mona（HCC） and their correlation with the clinical characteristics and their impact on the efficacy of sorafenib therapy. Methods The specimens of the patients who underwent surgical resection due to HCC in Sun Yat?sen Memorial Hospital and then received sorafenib therapy after the surgery were collected from January 2008 to December 2016. Immunohistochemical staining（IHC）was used to analyze the expression of SH3GL1 and p?ERK in these tissues. The information of the patients included the gender, age, status of HBsAg, AFP value, Child-Pugh stage of liver function, ECOG performance status before surgery, tumor differentiation degree, vascular invasion, extrahepatic metastasis, tumor number and tumor staging was divided into different groups. Further, the correlations between the IHC scores and the clinical factors and the prognosis of patients were analyzed. Results The positive rate of SH3GL1 and p-ERK in HCC samples were high, and there was positive correlation between these two proteins（P<0.001）. The strong expression of SH3GL1 was correlated with extrahepatic metastasis, multiple tumor and tumor staging while the strong expression of p?ERK was correlated with tumor staging. The risk factors that worsened the prognosis of HCC patients who received sorafenib treatment after surgical resection included age less than50 years old, strong expression of SH3GL1, strong expression of p-ERK, existence of extrahepatic metastasis and multiple tumor. Further, strong expression of SH3GL1, existence of extrahepatic metastasis and multiple tumor were the independent risk factor. Conclusion The expression of SH3GL1 and p-ERK were correlated with several tumor characteristics of HCC and the prognosis of patients, and high expression of these two proteins are risk factor for patients overall survival.

Key words: hepatocellular carcinoma, sorafenib, SH3GL1, drug resistance, p?ERK

摘要：

目的 研究SH3GL1和p?ERK在原发性肝癌组织中的表达以及二者对服用索拉非尼患者预后的影响。方法 收集我院自2008年1月至2016年12月期间因原发性肝癌进行手术治疗, 并且术后坚持口服索拉非尼的患者组织标本共73例，免疫组化分析患者组织中SH3GL1和p?ERK的表达情况，统计所有患者性别、年龄、术前HBsAg表达情况、术前AFP值、术前肝功能分级、体力状况评分、肿瘤分化程度、是否有脉管侵犯、是否有肝外转移病灶、肿瘤数量、肿瘤分期在内的多项临床指标，分析SH3GL1和p?ERK在HCC中的表达情况与这些指标的联系及其对患者预后的影响。结果 SH3GL1和p?ERK在原发性肝癌患者组织中阳性表达率高，并且二者的表达水平呈正相关关系（P<0.001）；SH3GL1的高表达与肿瘤有肝外转移、肿瘤多发和肿瘤分期相关，p?ERK的高表达则与患者肿瘤分期相关；影响肝癌术后服用索拉非尼患者总生存期的危险因素包括年龄低于50岁、SH3GL1高表达，p?ERK高表达、有肝外转移灶、肿瘤多发，其中SH3GL1高表达、有肝外转移和肿瘤多发为影响总预后的独立危险因素。结论 SH3GL1和p?ERK在原发性肝癌中的表达对于肝癌多项临床指标相关，并且二者的高表达是影响服用索拉非尼患者总生存期的危险因素。

关键词: 索拉非尼, p?ERK, SH3GL1, 原发性肝癌, 耐药